Cordis CrossFlex LC Stent Boasts 3.2% 30-Day Adverse Event Rate
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Cordis business is highlighting the CrossFlex LC coronary stent's low 3.2%, 30-day major adverse event rate as "among the best reported" following FDA approval of the device Sept. 14. Priced at $1,550-2,150 depending on size, the CrossFlex began shipments in the U.S. immediately following approval, the firm says.
You may also be interested in...
Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.